glyburide has been researched along with Metabolic Syndrome in 5 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 9.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 9.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 5.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 5.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| "Empagliflozin (EMPA) is a sodium-glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases." | 4.02 | Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin. ( Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tasi, WC; Wu, BN, 2021) |
| "Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC." | 2.72 | A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. ( Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Glyburide has replaced insulin as the more common pharmacotherapy for GDM over the past decade among those privately insured." | 1.40 | Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. ( Benjamin, DK; Boggess, K; Brookhart, MA; Camelo Castillo, W; Jonsson Funk, M; Stürmer, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jhuo, SJ | 1 |
| Liu, IH | 1 |
| Tasi, WC | 1 |
| Chou, TW | 1 |
| Lin, YH | 1 |
| Wu, BN | 1 |
| Lee, KT | 1 |
| Lai, WT | 1 |
| Camelo Castillo, W | 1 |
| Boggess, K | 1 |
| Stürmer, T | 1 |
| Brookhart, MA | 1 |
| Benjamin, DK | 1 |
| Jonsson Funk, M | 1 |
| Akbar, DH | 1 |
| Koshiba, K | 1 |
| Nomura, M | 1 |
| Nakaya, Y | 1 |
| Ito, S | 1 |
| Viberti, G | 1 |
| Lachin, J | 1 |
| Holman, R | 1 |
| Zinman, B | 1 |
| Haffner, S | 1 |
| Kravitz, B | 1 |
| Heise, MA | 1 |
| Jones, NP | 1 |
| O'Neill, MC | 1 |
| Freed, MI | 1 |
| Kahn, SE | 1 |
| Herman, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for glyburide and Metabolic Syndrome
| Article | Year |
|---|---|
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.
Topics: Blood Glucose; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Hu | 2003 |
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; | 2006 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; | 2006 |
2 other studies available for glyburide and Metabolic Syndrome
| Article | Year |
|---|---|
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Connexin 43; Connexins; Diet, High-Fat; Dise | 2021 |
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011.
Topics: Adolescent; Adult; Comorbidity; Diabetes, Gestational; Female; Glyburide; Humans; Hyperandrogenism; | 2014 |